Intrathecal mitozantrone has to be prohibited TO 
THE EDITOR
Anissa, a 30-month-old girl, was admitted in our hematology pediatric unit in May 1998 with severe anemia with purpura and general degradation. Neurologic clinical examination was absolutely normal. The blood test revealed: Hb: 38 g/l, WBC: 80 g/l with 25% of blasts, and platelets: 18 g/l. The bone marrow aspiration showed acute myelomonocytic leukemia (AML M4). Anissa was included in French Immunological Hematological Paediatric Society (SHIP) LAME 91 protocol. The first course of chemotherapy included i.v. mitozantrone and cytarabine and intrathecal chemotherapy with methotrexate, cytarabine and corticosteroids.
As the child was in the operating theater for central venous access setting under general anesthesia, we performed the first CNS fluid examination with injection of intrathecal chemotherapy as planned by protocol. This was done by a non-hematologist resident who did not know the color difference between methotrexate and mitozantrone. Cerebral fluid sample examination showed no blast cells. Six hours after the intrathecal injection, she presented with general seizures and was transferred to the intensive care unit, where a lumbar puncture was done. As there was doubt as to cerebral involvement, the planned intravenous chemotherapy was started immediately. Microbiological research and methotrexate dosage in cerebral fluid were negative. Given this surprising result, a mistake in the intrathecal therapy (mitozantrone injection instead of methotrexate) was suspected. Quantitative mitozantrone research in cerebral fluid sample was positive.
A cerebral CT scan under emergency conditions was normal. EEG showed severe signs of encephalopathy. Clinical evolution was dramatic with seizure relapses, vigil coma, progressive tetraplegia, cecity and surdity. A MRI scan made on day 2 revealed central gray nucleus and frontal cortex abnormal signals (Figure 1) . A second MRI scan made on day 30 showed more severe and large ischemic and hemorragic lesions: hypersignal of interhemispheric frontal cortex, head of both caudate nucleus, left pallidum and genu of internal capsule. After gadolinium injection, there was increased signal of left head of caudate nucleus and pallidum ( Figure 2) . A third MRI scan made on day 90 showed tetraventricular hydrocephaly and extension of the initial lesions.
Anissa died in January 1999 in severe neurological degradation without evidence of leukemia recurrence.
Three adults with neurological leukemia or lymphoma relapses were treated with intrathecal mitozantrone.
1-3 Doses per injection were lower than in the case of Anissa (0.8 to 2 mg vs 6.6 mg), but total doses were more important (25 mg for the highest total dose). The first case report was a 46-year-old man with isolated CNS relapse of diffuse lymphoblastic lymphoma. Complete clinical remission of neurological symptoms was obtained after multiple intrathecal mitozantrone injections. Three months later he presented with paraplegia and died 1 month after of systemic relapse. 1 The second report was a 51-year-old woman in third CNS relapse of AML-M3. A cytological remission was obtained after several intrathecal injections of 2 mg of mitozantrone, but the patient continued to deteriorate neurologically and became comatose and died. 2 The third case report was a 38-year-old man who presented with a third CNS relapse of acute lymphoblastic leukemia. He received three weekly mitozantrone intrathecal injections (2 mg). He presented with local pain after the second and the third one with reduced dosage (1 mg). Over a period of 2 weeks he developed paraplegia, although blast disappeared. Authors believe mitozantrone played a major part in causing paraplegia.
3 For the first two authors, the neurological degradation should be explained by leukemia relapse, but not by intrathecal mitozantrone toxicity. Moreover, the pharmacological firm producing this drug advised practicians against intrathecal use of mitozantrone 4 and neurotoxicity in monkeys was also demonstrated.
5
Our observation confirmed severe neurotoxicity of intrathecal mitozantrone in a child without neurological leukemia localization, and who did not receive any other neurotoxic drug. We think that mitozantrone use by intrathecal administration is absolutely prohibited.
JH Dalle
Unité Is there any genetic susceptibility to acute promyelocytic leukemia?
TO THE EDITOR Acute promyelocytic leukemia (APL) is a distinct subtype of acute myelogenous leukemia (AML) distinguished by a balanced reciprocal translocation between chromosomes 15 and 17 responsible for the molecular rearrangement PML/RAR␣. We read with interest the article by Bolognesi et al 1 concerning data on HLA association in acute promyelocytic leukemia (APL). The authors' data, obtained from 102 patients with newly diagnosed APL provided by the clinical centers belonging to the Italian Cooperative Group GIMEMA, showed a different distribution of alleles between bcr1 and bcr3 patients, and a statistically significant association between HLA-B13 and risk of relapse suggesting a possible identification of patients at high risk of relapse in which more aggressive consolidation therapies should be used. The HLA genes have always played an important part in the search for the hereditary contribution to a disease. Regarding leukemia, pioneering work showed that resistance and susceptibility to murine leukemia virus is mapped to the major histocompatibility complex gene region. In Bolognesi et al's report, 1 the comparison of HLA frequencies in Italian APL patients with those of an ethnically matched control population did not show any difference. Although realized on a smaller series, the frequency of HLA-A, -B, -Cw tested alleles (determined by serological typing) in our recent APL patients was quite similar to that reported in the Italian APL population (Table 1) . Despite an apparent similarity in HLA phenotypes among APL patients and a regular population, a genetic susceptibility to APL may be questionable. Indeed, different features suggest a genetic predisposition or susceptibility to APL related or not to exposure to distinct environmental factors. First of all, relationship between ethnicity and APL has been strongly suggested, APL cases being more frequent in patients from Latino origin. 2 Secondly, population studies have identified possible genetic markers of increased susceptibility to leukemia. 3 In order to illustrate this, we first report the observation of two cases of APL, sharing HLA alleles and bcr1 breakpoint, occurring in the same family, and then discuss the different features sustaining these data.
Case 1, a 35-year-old woman originating from the Christian community of Lebanon, was admitted to our hospital in October 1993. She was first hospitalized in Beirut in August 1993 complaining of bleeding gums and spontaneous bruising. Peripheral blood showed anemia, thrombopenia and white blood cell count of 2.2 × 10 9 /l (7% blast cells). Biological tests showed coagulation disorders with low fibrinogen levels and presence of fibrin degradation products. Bone marrow aspirates confirmed a diagnosis of AML, and the patient received three courses of chemotherapy (one course every 2 weeks) combining daunorubicin (20 mg/day for 4 days) with cytarabine (100 mg/day for 5 days) and etoposide (200 mg/day for 4 days). The patient developed pneumonia. Her WHO performance status progressively declined and her family decided on hospitalization in France. Upon arrival in our institution, peripheral blood showed pancytopenia. Pneumonia was proven to be due to aspergillosis and was treated by amphotericin B and then itraconazole. The bone marrow was markedly hypocellular, but had typical findings of APL with hypergranular blasts, many with multiple Auer rods. Cytogenetic according to our schedule combining oral ATRA therapy (45 mg/m 2 /day) from day 1 to complete remission (CR) achievement followed by EMA-timed sequential chemotherapy. While pneumonia was improving under itraconazole, neurological complications occurred on day 41 of ATRA therapy. The patient abruptly presented with headache and seizures without localized neurologic deficit. Cranial CT scan showed a right mass, in frontal and parietal areas, suggestive of subdural hematoma. Neurosurgical excision was successfully performed. CR was achieved by day 77. Then the patient received EMA-timed sequential chemotherapy combining mitoxantrone 12 mg/m 2 /day for 3 days, etoposide 200 mg/m 2 /day for 3 days, and cytarabine 500 mg/m 2 /day for two sequences of 3 days. Case 1 had three sibling donors (Table 2) . From HLA phenotypes, parents' haplotypes could be deduced showing a haplotype in common strongly suggesting a notion of consanguinity between them. Despite the presence of suitable familial donors, she received a second course of EMA chemotherapy as consolidation therapy. The patient is currently alive more than 6 years after CR achievement. She is still in cytological CR and has no detectable PML/RAR␣ rearrangement by RT-PCR determinations.
Case 2, a 56-year-old woman, was first admitted to our hospital in February 1995. She was related to case 1 (case 1's father's brother's wife), and came from the same village in Lebanon. Interrogation also revealed that she was case 1's mother's cousin (two generations). She was first hospitalized in Lebanon in January 1995 for AML and was treated by daunorubicin (40 mg/day for 2 days) and cytarabine (150 mg/day for 6 days). At arrival in our institution, peripheral blood showed anemia, thrombocytopenia and white blood cell count of 7 × 10 9 /l (63% blasts with abundance of Auer bodies). LDH level was at 1130 UI/l. Bone marrow aspirates showed an infiltration by leukemic cells with t(15;17) confirming the diagnosis of typical APL. Molecular biology showed PML/RAR␣ rearrangement with bcr1 breakpoint. HLA phenotype was A68 (or 69) A29 B7 B51 DR11 DR52 DQ7. Treatment was started according to the same schedule as in case 1. ATRA therapy was marked by side-effects: bilateral myodesopsia with beginning of venous thrombosis involving the left eye, bone pain and arthralgias, signs of pulmonary embolism. Despite those complications, ATRA was continued until CR achievement obtained by day 32. Then she received two courses of EMA-timed sequential chemotherapy. Aplasia following the second course of chemotherapy was marked by pulmonary aspergillosis that was successfully treated by amphotericin B then itraconazole. The patient is currently alive more than 5 years after CR achievement. She is still in cytological and molecular CR.
First of all, this observation described the occurrence of the same leukemia subtype (representing generally about 10% of all AML) in members of the same family. The two patients were related by case 1's mother who was case 2's cousin. Furthermore, they belonged to the same Lebanese community in which consanguinity seems relatively frequent as suggested by the expression of similar HLA alleles in the two patients and by the expression of a similar haplotype in case 1's parents. The two patients were also living in the same environment and leukemia occurred with a less than 2-year interval. Familial leukemia may be indicative of rare genes restricted to a given family, or it may be the outcome of exposure to a common environmental agent. Those two possibilities are not mutually exclusive. Heredity is of importance in some disorders that predispose individuals to leukemia such as ataxia-telangiectasia or Fanconi's anemia. Although findings of discordant leukemia in adolescent and adult twins have been described, convincing evidence for the origin of monozygotic
